Kura Oncology Inc

Discover how Kura Oncology is pioneering personalized therapies for high‑unmet‑need cancers—from lung to pancreatic—while navigating biotech volatility and fueling future breakthroughs.

FDA approves Kura Oncology’s KOMZIFTI for relapsed/refractory NPM1‑mutated AML, sparking investor confidence and potential upside as the drug moves to U.S. launch.

Kura Oncology, a clinical-stage biopharmaceutical company, is making significant strides in the development of personalized therapeutics for various cancers, with a focus on addressing unmet medical needs and improving patient outcomes in oncology.

Kura Oncology Inc, a clinical-stage biopharmaceutical company, presents a high-risk, high-reward investment opportunity due to its ambitious mission and volatile financial metrics.

Kura Oncology’s ziftomenib, a potential treatment for a difficult-to-treat blood cancer, has sparked both optimism and skepticism among investors and industry watchers as it awaits FDA approval.

Kura Oncology has submitted a New Drug Application (NDA) to the FDA for Ziftomenib, a potential breakthrough treatment for cancers with high unmet needs.